GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncorus Inc (OTCPK:ONCR) » Definitions » Property, Plant and Equipment

Oncorus (Oncorus) Property, Plant and Equipment : $59.07 Mil (As of Mar. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Oncorus Property, Plant and Equipment?

Oncorus's quarterly net PPE increased from Sep. 2022 ($76.88 Mil) to Dec. 2022 ($76.92 Mil) but then declined from Dec. 2022 ($76.92 Mil) to Mar. 2023 ($59.07 Mil).

Oncorus's annual net PPE increased from Dec. 2020 ($45.55 Mil) to Dec. 2021 ($68.45 Mil) and increased from Dec. 2021 ($68.45 Mil) to Dec. 2022 ($76.92 Mil).


Oncorus Property, Plant and Equipment Historical Data

The historical data trend for Oncorus's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncorus Property, Plant and Equipment Chart

Oncorus Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Property, Plant and Equipment
4.30 4.48 45.55 68.45 76.92

Oncorus Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.67 75.39 76.88 76.92 59.07

Oncorus Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Oncorus  (OTCPK:ONCR) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Oncorus Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Oncorus's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncorus (Oncorus) Business Description

Industry
Traded in Other Exchanges
N/A
Address
4 Corporate Drive, Andover, MA, USA, 01810
Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.
Executives
Brian J. Shea officer: Interim CEO C/O ONCORUS, INC., 4 CORPORATE DRIVE, ANDOVER MA 01810
Alexander Nolte officer: Interim CFO 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
James E Flynn director, 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas Fambrough director C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
Rick Wanstall officer: CFO and Treasurer C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Stephen Harbin officer: COO and Chief of Staff C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Eric Rubin director C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Christophe Queva officer: CSO and SVP, Research C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Luke Evnin director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Oncology Impact Fund (cayman) Management L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Asset Management Investors Sunstates Fund Llc 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Ansbert Gadicke 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

Oncorus (Oncorus) Headlines